摘要:
Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.
摘要:
Prodrugs of levodopa, methods of making prodrugs of levodopa, methods of using prodrugs of levodopa, and compositions of prodrugs of levodopa are disclosed. Wherein Q is selected from X-CO-, and -CO-X-; X is selected from-O-, and -NR 6 -; n is an integer from 2 to 4; R 5 is selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, and substituted heteroarylalkyl; and when Q is -X--CO-, R5 is further selected from alkoxy, substituted alkoxy, cycloalkoxy, and substituted cycloalkoxy.
摘要翻译:公开了左旋多巴的前药,制备左旋多巴的前药的方法,使用左旋多巴的前药的方法和左旋多巴的前药组合物。 其中Q选自X-CO-和-CO-X-; X选自-O-,-NR 6 - ; n是2至4的整数; R 5选自氢,烷基,取代的烷基,芳基,取代的芳基,芳基烷基,取代的芳基烷基,环烷基,取代的环烷基,杂烷基,取代的杂烷基,环杂烷基,取代的环杂烷基,杂芳基,取代的杂芳基,杂芳基烷基和取代的杂芳基烷基。 当Q是-X-CO-时,R5进一步选自烷氧基,取代的烷氧基,环烷氧基和取代的环烷氧基。
摘要:
Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.
摘要:
Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.
摘要:
The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by LRRK2 kinase activity, for example Parkinson's disease or Alzheimer's disease.
摘要:
Acyloxyalkyl carbamate prodrugs of α-amino acids, pharmaceutical compositions thereof, methods of making acyloxyalkyl carbamate prodrugs of α-amino acids and methods of using acyloxyalkyl carbamate prodrugs of α-amino acids, and pharmaceutical compositions thereof to treat a disease are disclosed. Acyloxyalkyl carbamate prodrugs of α-amino acids suitable for oral administration using sustained release dosage forms are also disclosed.
摘要:
(2R)-2-Phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and crystalline form thereof, methods of making the same, pharmaceutical compositions thereof, and methods of using the same to treat diseases or disorders such as Parkinson's disease are provided.
摘要:
(2R)-2-Phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and crystalline form thereof, methods of making the same, pharmaceutical compositions thereof, and methods of using the same to treat diseases or disorders such as Parkinson's disease are provided.
摘要:
Prodrugs of levodopa, methods of making prodrugs of levodopa, methods of using prodrugs of levodopa, and compositions of prodrugs of levodopa are disclosed. Formula (I), n is an integer from 1 to 6; R 5 is selected from alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalyl, substituted heteroalyl, heteroalylalkyl, and substituted heteroalylalkyl.
摘要翻译:公开了左旋多巴的前药,制备左旋多巴的前药的方法,使用左旋多巴的前药的方法和左旋多巴的前药组合物。 式(I)中,n为1至6的整数; R 5选自烷基,取代的烷基,芳基,取代的芳基,芳基烷基,取代的芳基烷基,环烷基,取代的环烷基,杂烷基,取代的杂烷基,环杂烷基,取代的环杂烷基,杂芳基,取代杂芳基,杂芳基烷基和取代的杂芳烷基。
摘要:
Acyloxyalkyl carbamate prodrugs of a-amino acids, pharmaceutical compositions thereof, methods of making acyloxyalkyl carbamate prodrugs of a-amino acids and methods of using acyloxyalkyl carbamate prodrugs of a-amino acids, and pharmaceutical compositions thereof to treat a disease are disclosed. Acyloxyalkyl carbamate prodrugs of a-amino acids suitable for oral administration using sustained release dosage forms are also disclosed.